Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function

Eur J Neurosci. 2001 Mar;13(5):889-98. doi: 10.1046/j.0953-816x.2000.01453.x.

Abstract

In this study we investigated, using in vivo microdialysis and single unit recordings, the role of serotonin4 (5-HT4) receptors in the control of nigrostriatal and mesoaccumbal dopaminergic (DA) pathway activity. In freely moving rats, the 5-HT4 antagonist GR 125487 (1 mg/kg, i.p.), without effect on its own, significantly reduced the enhancement of striatal DA outflow induced by 0.01 (-35%) and 0.1 (-66%), but not 1 mg/kg, s.c. haloperidol (HAL). Intrastriatal infusion of GR 125487 (1 microM) had no influence on basal DA outflow, but attenuated (-49%) the effect of 0.01 mg/kg HAL. Systemic administration of GR 125487 modified neither basal nor 0.01 mg/kg HAL-stimulated accumbal DA outflow. In halothane-anaesthetized rats, 1 or 10 mg/kg GR 125487, without effect by itself, failed to modify the changes in accumbal and striatal DA outflow elicited by electrical stimulation (300 microA, 1 ms, 20 Hz, 15 min) of the dorsal raphe nucleus. Finally, GR 125487 (444 microg/kg, i.v.), whilst not affecting basal firing of DA neurons within either the substantia nigra or the ventral tegmental area, reduced HAL-stimulated (1--300 microg/kg, i.v.) impulse flow of nigrostriatal DA neurons only. These results indicate that 5-HT4 receptors exert a facilitatory control on both striatal DA release and nigral DA neuron impulse flow only when nigrostriatal DA transmission is under activated conditions. Furthermore, they indicate that the striatum constitutes a major site for the expression of the control exerted by 5-HT4 receptors on DA release. In contrast, 5-HT4 receptors have no influence on mesoaccumbal DA activity in either basal or activated conditions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Animals
  • Dopamine / metabolism*
  • Dopamine Antagonists / pharmacology
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Extracellular Space / metabolism
  • Haloperidol / pharmacology
  • Indoles / pharmacology
  • Male
  • Neostriatum / cytology
  • Neostriatum / drug effects
  • Neostriatum / metabolism*
  • Neural Pathways / cytology
  • Neural Pathways / drug effects
  • Neural Pathways / metabolism*
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / metabolism
  • Nucleus Accumbens / cytology
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / metabolism*
  • Raphe Nuclei / cytology
  • Raphe Nuclei / drug effects
  • Raphe Nuclei / metabolism
  • Rats
  • Receptors, Serotonin / drug effects
  • Receptors, Serotonin / metabolism*
  • Receptors, Serotonin, 5-HT4
  • Serotonin / metabolism
  • Serotonin Antagonists / pharmacology
  • Substantia Nigra / cytology
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*
  • Sulfonamides / pharmacology
  • Ventral Tegmental Area / cytology
  • Ventral Tegmental Area / drug effects
  • Ventral Tegmental Area / metabolism*

Substances

  • Dopamine Antagonists
  • Indoles
  • Receptors, Serotonin
  • Serotonin Antagonists
  • Sulfonamides
  • Receptors, Serotonin, 5-HT4
  • Serotonin
  • Haloperidol
  • Dopamine
  • GR 113808